5氨基酸处方模式和性结肠炎患者治疗结果的十年趋势:对韩国医疗保险数据的分析
Soo Jung Park1,2, Sang Won Park3, Jae Hee Cheon4,5
1Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Digestive diseases and sciences
|December 23, 2025
概括
在亚洲的真实世界性结肠炎治疗中,出现了转向更高剂量的5 - 氨基酸 (5-ASA) 组合疗法的转变. 这一趋势符合指导方针,即使用直肠单疗法减少.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据研究研究.
背景情况:
- 性结肠炎 (UC) 患病率在亚洲正在上升,但对使用5 - 氨基酸 (5-ASA) 的现实数据有限.
- 了解当前的5-ASA处方模式对于优化该地区的UC管理至关重要.
研究的目的:
- 分析韩国性结肠炎患者的5-ASA剂量和施用方法的趋势.
- 评估与这些不断变化的处方模式相关的治疗结果.
主要方法:
- 利用了2008-2019年韩国国家医疗保险索赔数据.
- 在UC患者中分析了每日平均5-ASA剂量和给药方式.
- 评估治疗结果,包括反应不足,住院和手术率.
主要成果:
- 观察到直肠单一治疗的减少和口服和直肠联合治疗的增加.
- 自2013年以来,高剂量5-ASA (≥2g/天) 处方显著增加.
- 每1000人/年发生率:51.16个是不充分反应,13.40个是住院治疗,1.13个是手术.
结论:
- 十年来,5-ASA的处方模式转向高剂量组合疗法,远离直肠单疗.
- 这一转变符合当前治疗性结肠炎的临床指南.
- 现实世界的数据为亚洲UC的不断发展的治疗策略提供了洞察力.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
416
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
416
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
405
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
405
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
454
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
454
Inflammatory Bowel Disease IV: Pharmacological Management
439
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
439
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K


